Hypoglycemia: New Definitions and Regulatory Implications
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Hypoglycemia is the limiting factor in controlling glucose levels in Diabetes. Rather than being a side effect, hypoglycemia is the mechanism of action for insulin therapy, with a very narrow therapeutic window. Until recently, regulatory bodies listed hypoglycemia only as an adverse effect of therapy; however, one insulin preparation is now recognized and labelled as reducing the risk of severe hypoglycemia. This paper describes internationally agreed upon definitions for hypoglycemia and proposed regulatory approaches for recognition and labeling of diabetes therapies to facilitate personalized care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 1×
“33 The ADA and EASD recommend utilization of CGM, together with patient-reported outcomes, as an inherent component of regulatory trials for drug approval.”
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471 · cited 1×
“9 However, many have argued that hypoglycemia is a marker for frailty, as temporal causal relationships are difficult to demonstrate.”
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 2×
“29 Controlled clinical trials in type 1 diabetes demonstrated a significant reduction in time 70mg/dL, as well as 50mg/dL in those using CGM compared with the control SMBG. 30 This was substantiated with a 72% reduction in hypoglycemic events in a high-risk population with a history of severe hypoglycemia or hypoglycem…”
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
International Hypoglycaemia Study Group (2017) · Diabetes Care · doi:10.2337/dc16-2215 · Cited by 608
Efficacy and safety of degludec versus glargine in type 2 diabetes.
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574
Heinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522
Ratner, R. E., Hirsch, I. B., Neifing, J. L., Garg, S. K., Mecca, T. E., & Wilson, C. A. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.639 · Cited by 455
Self-citationMechanisms of hypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1215228 · Cited by 433 · cited 1×
“27 The FDA has reviewed several continuous glucose monitoring (CGM) systems for clinical use recently with greater accuracy on the hypoglycemic end and approved them.”
Chow, E., Bernjak, A., Williams, S., Fawdry, R. A., Hibbert, S., Freeman, J., Sheridan, P. J., & Heller, S. R. (2014) · Diabetes · doi:10.2337/db13-0468 · Cited by 403 · cited 1×
“11 It is very apparent, however, that hypoglycemic events short of loss of consciousness or requiring the assistance of Division of Endocrinology, Diabetes, and Metabolism, Georgetown University School of Medicine, Washington, District of Columbia. a third party have significant impact on patient…”
The impact of non-severe hypoglycemic events on work productivity and diabetes management
Brod, M., Christensen, T., Thomsen, T. L., & Bushnell, D. M. (2011) · Value in Health · doi:10.1016/j.jval.2011.02.001 · Cited by 284 · cited 1×
“12 Although people with type 2 diabetes experience less hypoglycemia (25% with weekly episodes), by virtue of their significant increased number, more type 2 diabetes individuals suffer hypoglycemia than do type 1 diabetes individuals.”
Chico, A., Vidal-Ríos, P., Subirà, M., & Novials, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1153 · Cited by 235 · cited 1×
“28 More recently, a presentation at the 77th Scientific Sessions of the ADA showed that individuals with type 1 diabetes had an overall rate of hypoglycemia of 5.8 events/patient-week corresponding to 10.1 h with hypoglycemia/patient-week.”
InfluentialLane, W., Bailey, T. S., Gerety, G., Gumprecht, J., Philis-Tsimikas, A., Hansen, C. T., Nielsen, T. S. S., Warren, M., Group Information, & 1, T. S. (2017) · JAMA · doi:10.1001/jama.2017.7115 · Cited by 206 · cited 1×
“26 The FDA following the lead of the European Medicines Agency (EMA) in March 2017 recognized the profound difference in severe hypoglycemia between insulin glargine and insulin degludec by including the data from the DE-VOTE Trial in the degludec label.”
Charleer, S., Mathieu, C., Nobels, F., De Block, C., Radermecker, R. P., Hermans, M. P., Taes, Y., Vercammen, C., T'Sjoen, G., Crenier, L., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02498 · Cited by 196 · cited 1×
“32 Results in type 2 diabetes are less dramatic, due to the decreased frequency of hypoglycemia.”
Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations
Petrie, J. R., Peters, A. L., Bergenstal, R. M., Holl, R. W., Fleming, G. A., & Heinemann, L. (2017) · Diabetes Care · doi:10.2337/dci17-0043 · Cited by 135
Electrocardiographic Alterations during Hyperinsulinemic Hypoglycemia in Healthy Subjects
Laitinen, T., Lyyra‐Laitinen, T., Huopio, H., Vauhkonen, I., Halonen, T., Hartikainen, J., Niskanen, L., & Laakso, M. (2008) · Annals of Noninvasive Electrocardiology · doi:10.1111/j.1542-474x.2008.00208.x · Cited by 107 · cited 1×
“10 Individuals with type 2 diabetes and cardiovascular disease demonstrated a variety of arrhythmias in association with hypoglycemia, including bradycardia, atrial, and ventricular ectopy.”
Cited by
Cappellani, D., Macchia, E., Falorni, A., & Marchetti, P. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s219438 · Cited by 138
Cummings, C., Jiang, A., Sheehan, A., Ferraz‐Bannitz, R., Puleio, A., Simonson, D. C., Dreyfuss, J. M., & Patti, M. E. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15096 · Cited by 27
Ata, F., Choudry, H., Khan, A. A., Anum, Khamees, I., Al‐sadi, A., Mohamed, A., Malkawi, L., & Aljaloudi, E. (2024) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.471 · Cited by 18
Hoffman, E. G., D’Souza, N. C., Liggins, R. T., & Riddell, M. C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1295639 · Cited by 13
“…in adults with T1D than T2D (McCoy et al., 2012; Aronson et al., 2018), but owing to disease prevalence (~20-fold that of T1D globally), T2D now accounts for the majority of severe diabetes-related hypoglycemic events (i.e., those resulting in hospitalization) (Heller et al., 2007; Ratner, 2018).”
Background
Metadata
- Authors
- Ratner, R. E.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2018-06
- Volume
- 20
- Issue
- S2
- Pages
- S2-50-S2-53
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2805796697
- Cited by
- 49
- References
- 17
- FWCI
- 3.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.